.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as general survival, causing FDA approval and also a brand-new therapy option for clients.